The NHS (UK) is losing up to ?300 million a year as a result of GPs choosing expensive brands of medicine, a report by the National Audit Office (NAO) has found.
The NHS is losing up to £300 million a year as a result of GPs choosing expensive brands of medicine, a report by the National Audit Office (NAO) has found. The report showed the great differences in prescribing between primary care trusts nationwide. It found that £200 million could be saved if all primary care trusts prescribed as efficiently as the top 25% of their peers. And if all trusts followed the examples of the top 10%, the NAO report said, in excess of £300 million could be saved.
It also said about £100 million per year was wasted on drugs, which were not used, and highlighted the 60% increase in the primary care drugs bill over the last decade. The committee called on the Department of Health to produce more accurate figures on the wastage of drugs and review why patients fail to take them.
Edward Leigh MP, chairman of the Committee for Public Accounts argued that the report "clearly demonstrates that GPs are often not providing value for money for the NHS in the way they prescribe drugs and medicines." He argued that small changes to how GPs prescribe could "free up a lot of money for our struggling NHS". Leigh also said the Department of Health must get "a better grip on the scale of the problem and the reasons it occurs", claiming that until it does so "they won't be able to put a stop to this waste".Auditor general Sir John Bourn, the head of the NAO, said: "There is significant scope for the NHS to improve the value for money of prescribing in primary care. If GPs more often followed official guidelines and prescribed generic and other cheaper drugs where suitable, then there would be more money to treat patients and pay for expensive or innovative treatments."
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.